PB 43 D
Alternative Names: PB-43-DLatest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Phanes Biotech
- Class Antibodies; Antidementias
- Mechanism of Action Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Tauopathies
Most Recent Events
- 07 Nov 2024 Preclinical trials in Alzheimer's disease in USA (IV) prior to November 2024 (Phanes Biotech Pipeline, November 2024)
- 07 Nov 2024 Preclinical trials in Tauopathies in USA (IV) prior to November 2024 (Phanes Biotech Pipeline, November 2024)
- 07 Nov 2024 Pharmacodynamics data from a preclinical study in Alzheimer’s disease and Tauopathies released by Phanes Biotech prior to November 2024 (Phanes Biotech Pipeline, November 2024)